The development of first-, second-, and third-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the clinical outcomes of advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients [1,2,3,4,5]. Here, EGFR is linked to non-small cell lung carcinoma.